{"id":23358,"date":"2025-04-13T17:39:37","date_gmt":"2025-04-13T17:39:37","guid":{"rendered":"https:\/\/globalsourcechemicals.com\/?post_type=product&p=23358"},"modified":"2025-10-03T07:45:12","modified_gmt":"2025-10-03T07:45:12","slug":"dmxe-40-mg-kulur-deoxymetoxetamins","status":"publish","type":"product","link":"https:\/\/globalsourcechemicals.com\/is\/bud\/arylsyklohexylamin\/dmxe-40-mg-kulur-deoxymetoxetamins\/","title":{"rendered":"DMXE 40 mg k\u00falur (deox\u00fdmetoxetam\u00edn)"},"content":{"rendered":"

DMXE (Deoxymetoxetamine) 40 mg k\u00falur \u2013 V\u00edsindaleg v\u00f6ruuppl\u00fdsingar<\/span><\/span><\/strong><\/h3>\n

\ud83d\udd2cEfnafr\u00e6\u00f0ilegar uppl\u00fdsingar<\/span><\/span><\/strong><\/h4>\n

DMXE (2\u2032-Oxo-PCE-d10) er ranns\u00f3knarefni sem tilheyrir flokki ar\u00fdls\u00fdkl\u00f3hex\u00fdlam\u00edna, byggingarlega skyld MXE (metoxetam\u00edni) og ketam\u00edni. \u00deessir k\u00falur eru samsettar fyrir n\u00e1kv\u00e6mar v\u00edsindaranns\u00f3knir.<\/span><\/span><\/p>\n

Kjarnabreytur:<\/span><\/span><\/em><\/p>\n

    \n
  • \n

    IUPAC-heiti<\/span><\/span><\/strong> 2-(3,4-d\u00edmet\u00fdlfen\u00fdl)-2-(et\u00fdlam\u00edn\u00f3)s\u00fdkl\u00f3hexan\u00f3n<\/span><\/span><\/p>\n<\/li>\n

  • \n

    Sameindaform\u00fala<\/span><\/span><\/strong> C\u2081\u2086H\u2082\u2083NO<\/span><\/span><\/p>\n<\/li>\n

  • \n

    M\u00f3l\u00feungi<\/span><\/span><\/strong> : 245,36 g\/m\u00f3l<\/span><\/span><\/p>\n<\/li>\n

  • \n

    Hreinleiki<\/span><\/span><\/strong> : \u226598% (GC-MS greining)<\/span><\/span><\/p>\n<\/li>\n

  • \n

    L\u00f6gun<\/span><\/span><\/strong> K\u00falur, 4 mm \u00ed \u00feverm\u00e1l<\/span><\/span><\/p>\n<\/li>\n

  • \n

    Litur<\/span><\/span><\/strong> Lj\u00f3s beige til hv\u00edtt<\/span><\/span><\/p>\n<\/li>\n

  • \n

    Leysni<\/span><\/span><\/strong> 15 mg\/ml \u00ed vatni (vi\u00f0 25\u00b0C)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

    \ud83e\uddeaV\u00edsindaleg notkun<\/span><\/span><\/strong><\/h4>\n
      \n
    1. \n

      Taugalyfjafr\u00e6\u00f0ilegar ranns\u00f3knir<\/span><\/span><\/strong> :<\/span><\/span><\/p>\n

        \n
      • \n

        Ranns\u00f3knir \u00e1 NMDA vi\u00f0takablokkun<\/span><\/span><\/p>\n<\/li>\n

      • \n

        Samspilsranns\u00f3knir \u00e1 Sigma-1 vi\u00f0taka<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

      • \n

        Atferlisfr\u00e6\u00f0ileg taugav\u00edsindi<\/span><\/span><\/strong> :<\/span><\/span><\/p>\n

          \n
        • \n

          \u00c1hrif \u00e1 n\u00e1msheg\u00f0un hj\u00e1 tilraunad\u00fdrum<\/span><\/span><\/p>\n<\/li>\n

        • \n

          Skammtah\u00e1\u00f0 sundrunar\u00e1hrif<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

        • \n

          S\u00e1lfr\u00e6\u00f0ileg lyfjafr\u00e6\u00f0i<\/span><\/span><\/strong> :<\/span><\/span><\/p>\n

            \n
          • \n

            Samanbur\u00f0arranns\u00f3knir vi\u00f0 skyld sundrunarefni<\/span><\/span><\/p>\n<\/li>\n

          • \n

            Ranns\u00f3knir \u00e1 taugaplast\u00edskum \u00e1hrifum<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n

            \u2696\ufe0fR\u00e1\u00f0lag\u00f0ar ranns\u00f3knarreglur<\/span><\/span><\/strong><\/h4>\n

            Tilraunalei\u00f0beiningar:<\/span><\/span><\/em><\/p>\n

            \n\n\n\n\n\n\n\n
            Fyrirmynd<\/span><\/span><\/th>\nSkammtar<\/span><\/span><\/th>\nT\u00ed\u00f0ni<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n
            \u00cd tilraunaglasi<\/span><\/span><\/td>\n10-50 m\u00edkr\u00f3m\u00f3l<\/span><\/span><\/td>\nEin \u00fatsetning<\/span><\/span><\/td>\n<\/tr>\n
            L\u00edtil nagd\u00fdr<\/span><\/span><\/td>\n5-20 mg\/kg<\/span><\/span><\/td>\n1x\/dag (h\u00e1mark 3 dagar)<\/span><\/span><\/td>\n<\/tr>\n
            Pr\u00edmatar<\/span><\/span><\/td>\n1-5 mg\/kg<\/span><\/span><\/td>\nEinn skammtur<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

            *Athugi\u00f0: \u00d3l\u00ednuleg lyfjahv\u00f6rf yfir 25 mg\/kg*<\/span><\/span><\/p>\n

            \u26a0\ufe0f\u00d6ryggisuppl\u00fdsingar og \u00e1h\u00e6ttust\u00fdring<\/span><\/span><\/strong><\/h4>\n
              \n
            1. \n

              Eiturefnafr\u00e6\u00f0ilegar uppl\u00fdsingar<\/span><\/span><\/strong> :<\/span><\/span><\/p>\n

                \n
              • \n

                LD\u2085\u2080 (rotta, um munn): 320 mg\/kg<\/span><\/span><\/p>\n<\/li>\n

              • \n

                NOAEL: 5 mg\/kg\/dag (7 daga ranns\u00f3kn)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

              • \n

                Aukaverkanasvi\u00f0<\/span><\/span><\/strong> :<\/span><\/span><\/p>\n

                  \n
                • \n

                  <10 mg: F\u00ednleg \u00e1hrif \u00e1 heg\u00f0un<\/span><\/span><\/p>\n<\/li>\n

                • \n

                  10-30 mg: \u00d3samh\u00e6f\u00f0 hreyfing<\/span><\/span><\/p>\n<\/li>\n

                • \n
                  \n

                  30 mg: Hugsanleg \u00f6ndunarb\u00e6ling<\/span><\/span><\/p>\n<\/blockquote>\n<\/li>\n<\/ul>\n<\/li>\n

                • \n

                  Mikilv\u00e6g samskipti<\/span><\/span><\/strong> :<\/span><\/span><\/p>\n

                    \n
                  • \n

                    H\u00e6ttulegt<\/span><\/span><\/strong> \u00d3p\u00ed\u00f3\u00ed\u00f0ar, GABA-erg\u00edsk efni<\/span><\/span><\/p>\n<\/li>\n

                  • \n

                    \u00c1h\u00e6ttusamt<\/span><\/span><\/strong> \u00d6rvandi efni, MAO-hemlar<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n

                    \ud83d\udccaG\u00e6\u00f0aeftirlit og greiningarg\u00f6gn<\/span><\/span><\/strong><\/h4>\n
                      \n
                    • \n

                      HPLC hreinleiki<\/span><\/span><\/strong> 98,5% (C18 s\u00fala, 70:30 H\u2082O:MeCN)<\/span><\/span><\/p>\n<\/li>\n

                    • \n

                      Einsleitni<\/span><\/span><\/strong> \u00b15% \u00feyngdarfr\u00e1vik (n=20 k\u00falur)<\/span><\/span><\/p>\n<\/li>\n

                    • \n

                      Sundrunart\u00edmi<\/span><\/span><\/strong> <15 m\u00edn\u00fatur (\u00ed magasafa samt\u00edmis)<\/span><\/span><\/p>\n<\/li>\n

                    • \n

                      St\u00f6\u00f0ugleikag\u00f6gn<\/span><\/span><\/strong> :<\/span><\/span><\/p>\n

                        \n
                      • \n

                        Geymslu\u00feol: 24 m\u00e1nu\u00f0ir vi\u00f0 15-25\u00b0C<\/span><\/span><\/p>\n<\/li>\n

                      • \n

                        Rakavi\u00f0kv\u00e6mni: <0,5% \u00feyngdaraukning (93% RH)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n

                        \u2753Algengar ranns\u00f3knarspurningar<\/span><\/span><\/strong><\/h4>\n

                        Spurning 1: Hver er verkunarh\u00e1ttur?<\/span><\/span><\/strong>
                        \n A: A\u00f0al NMDA vi\u00f0takablokkun me\u00f0 annars stigs h\u00f6mlun \u00e1 enduruppt\u00f6ku d\u00f3pam\u00edns.<\/span><\/span><\/p>\n

                        Spurning 2: Hvernig ber virknin saman vi\u00f0 ketam\u00edn?<\/span><\/span><\/strong>
                        \n A: ~0,6 sinnum styrkleiki ketam\u00edns en lengri helmingunart\u00edmi (4-6 klukkustundir).<\/span><\/span><\/p>\n

                        Spurning 3: Eru einhverjar taugaeitur\u00e1h\u00e6ttu\u00e1h\u00e6ttu?<\/span><\/span><\/strong>
                        \n A: Olney-s\u00e1r s\u00e1ust ekki vi\u00f0 <50 mg\/kg (ranns\u00f3kn \u00e1 rottum).<\/span><\/span><\/p>\n

                        Spurning 4: Hver er besta geymslua\u00f0fer\u00f0in?<\/span><\/span><\/strong>
                        \n A: \u00cd upprunalegum umb\u00fa\u00f0um vi\u00f0 15-25\u00b0C, vari\u00f0 gegn raka.<\/span><\/span><\/p>\n

                        \ud83d\udcccRanns\u00f3knartakmarkanir<\/span><\/span><\/strong><\/h4>\n
                          \n
                        • \n

                          Takmarka\u00f0ar uppl\u00fdsingar um langt\u00edmagj\u00f6f<\/span><\/span><\/p>\n<\/li>\n

                        • \n

                          \u00d3\u00feekkt \u00e1hrif \u00e1 flutning gl\u00fatamats<\/span><\/span><\/p>\n<\/li>\n

                        • \n

                          Breytileg l\u00edffr\u00e6\u00f0ileg umbreyting milli tegunda<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                          \ud83d\udd0dNi\u00f0ursta\u00f0a fyrir v\u00edsindamenn<\/span><\/span><\/strong><\/h4>\n

                          DMXE 40 mg t\u00f6flur bj\u00f3\u00f0a upp \u00e1 st\u00f6\u00f0la\u00f0a samsetningu fyrir n\u00e1kv\u00e6mar ranns\u00f3knir \u00e1 sundrun lyfsins, me\u00f0 st\u00f6\u00f0ugri skammtagj\u00f6f og g\u00f3\u00f0um st\u00f6\u00f0ugleika. Pillurnar au\u00f0velda megindlega gj\u00f6f \u00ed d\u00fdraranns\u00f3knum.<\/span><\/span><\/p>\n

                          V\u00edsindaleg fyrirvari: \u00deessi vara er eing\u00f6ngu \u00e6tlu\u00f0 til ranns\u00f3kna in vitro og vi\u00f0urkenndra forkl\u00edn\u00edskra ranns\u00f3kna. Ekki til notkunar fyrir menn. Allar tilraunir ver\u00f0a a\u00f0 vera \u00ed samr\u00e6mi vi\u00f0 gildandi si\u00f0areglur og gildandi regluger\u00f0ir. Vinsamlegast athugi\u00f0 s\u00e9rstaka st\u00f6\u00f0u ge\u00f0virkra ranns\u00f3knarefna \u00ed ykkar l\u00f6gs\u00f6gu.<\/span><\/span><\/em><\/p>","protected":false},"excerpt":{"rendered":"

                          DMXE eiginleikar<\/span><\/span><\/span><\/span><\/h3>\n

                          Samheiti:<\/span><\/span><\/span><\/span><\/strong> Deox\u00fdmetoxetam\u00ednh\u00fddr\u00f3kl\u00f3r\u00ed\u00f0 <\/span><\/span><\/span><\/span>
                          \nCAS-n\u00famer:<\/span><\/span><\/span><\/span><\/strong> 681440-83-5 <\/span><\/span><\/span><\/span>
                          \nForm\u00fala:<\/span><\/span><\/span><\/span><\/strong> 5-deh\u00fddr\u00f3-1,3-k\u00edn\u00f3d\u00edmetan <\/span><\/span><\/span><\/span>
                          \nM\u00f3lmassi:<\/span><\/span><\/span><\/span><\/strong> 103,14 g\/m\u00f3l <\/span><\/span><\/span><\/span>
                          \nHreinleiki:<\/span><\/span><\/span><\/span><\/strong> >97%<\/span><\/span><\/span><\/span><\/p>","protected":false},"featured_media":27873,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[71,406,429,324],"product_tag":[326],"class_list":{"0":"post-23358","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-arylcyclohexylamine","7":"product_cat-dmxe","8":"product_cat-dmxe-pellets","9":"product_cat-pellets-for-pellet","10":"product_tag-nl","12":"first","13":"instock","14":"taxable","15":"shipping-taxable","16":"purchasable","17":"product-type-variable"},"_links":{"self":[{"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product\/23358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/comments?post=23358"}],"version-history":[{"count":5,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product\/23358\/revisions"}],"predecessor-version":[{"id":28083,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product\/23358\/revisions\/28083"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/media\/27873"}],"wp:attachment":[{"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/media?parent=23358"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product_brand?post=23358"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product_cat?post=23358"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product_tag?post=23358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}